Sunflower Seed Oil-Enriched Product Can Inhibit Ehrlich Solid Tumor Growth in Mice

Silva, Lucilene A.; Nascimento, Kátia A.F.; Maciel, Márcia C.G.; Pinheiro, Mayara T.; Sousa, Paulo R.A.; Ferreira, Susanne C.P.; Azevedo, Ana Cláudia; Guerra, Rosane Nassar Meireles; Nascimento, Flávia R.F.

doi:10.1159/000091308

Cited by 18 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Solid Ehrlich Carcinoma (SEC) xenograft model induced in mice was established as a valid model that is commonly used to investigate different chemotherapeutic treatment strategies for breast cancer [32]. This model reflects a high degree of malignancy due to its high virulence ability, rapid development and highly infiltrative nature [33].…”

Section: Resultsmentioning

confidence: 99%

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

Haggag

Matchett

Falconer

et al. 2019

Cancers

View full text Add to dashboard Cite

The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (NPs). A modified double emulsion solvent evaporation technique was used to optimise the physicochemical properties of these peptide-loaded biodegradable NPs. The anti-cancer activity of peptide-loaded NPs was studied in vitro using Ran-expressing metastatic breast (MDA-MB-231) and lung cancer (A549) cell lines, and in vivo using Solid Ehrlich Carcinoma-bearing mice. The anti-metastatic activity of peptide-loaded NPs was investigated using migration, invasion and colony formation assays in vitro. A PEG-PLGA-nanoparticle encapsulating N-terminal peptide showed a pronounced antitumor and anti-metastatic action in lung and breast cancer cells in vitro and caused a significant reduction of tumor volume and associated tumor growth inhibition of breast cancer model in vivo. These findings suggest that the novel inhibitory peptides encapsulated into PEGylated PLGA NPs are delivered effectively to interact and deactivate Ran. This novel Ran-targeting peptide construct shows significant potential for therapy of breast cancer and other cancers mediated by Ran overexpression.

show abstract

Section: Resultsmentioning

confidence: 99%

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

Haggag

Matchett

Falconer

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…However, there is limited information about the mechanisms by which b-blockers could impact the course and survival in cases of breast cancer. In this research work, SEC-bearing model in mice was established as a valid model that was frequently used to investigate chemotherapeutic strategies for breast cancer [33]. This model is typically of high virulence, quick development and infiltrative nature, reflecting its high-grade malignancy [34].…”

Section: Discussionmentioning

confidence: 99%

Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice

Abdin

Soliman

Saied

2014

Pharmacological Reports

View full text Add to dashboard Cite

show abstract

“…It was commonly used to study the effect of different chemotherapeutic drugs on the treatment of breast cancer. 45 This model reflects highgrade malignancy due to its high virulence ability, infiltrative nature, and quick development. 46 Therefore, the SEC model is used to study the anti-cancer effect of HK against breast cancer after systemic administration in vivo.…”

Section: In Vivo Anti-tumor Activitymentioning

confidence: 99%

<p>Design, Formulation and in vivo Evaluation of Novel Honokiol-Loaded PEGylated PLGA Nanocapsules for Treatment of Breast Cancer</p>

Haggag¹,

Ibrahim²,

Hafiz³

2020

IJN

View full text Add to dashboard Cite

Background: Honokiol (HK) is a common herbal medicine extracted from magnolia plants. Low aqueous solubility and limited bioavailability of HK have hindered its clinical application, especially for cancer treatment. Nano-drug delivery system has the potential to enhance HK delivery and therefore, enhance its anti-cancer activity. Purpose: The study's aim is to design novel PEGylated-PLGA polymeric nanocapsules (NCs) for HK delivery to breast tumor-bearing mice after systemic administration. Methods: Formulation of different HK-loaded NCs and their physio-chemical characterization were optimized through the use of different formulation variables. The antitumor activity of the HK-loaded NCs was investigated both in vitro using MCF-7 and EAC breast cancer cell lines and in vivo using solid Ehrlich carcinoma (SEC) breast cancer model. Results: The optimum HK-loaded NCs were prepared from 15% PEG-PLGA diblock copolymer and exhibited the lowest nano size of 125 nm, smooth spherical morphology, highest drug loading of 94% and highest cellular uptake into breast cancer cells. HK-loaded PEGylated NCs can effectively inhibit the in vitro cell growth of breast cancer cells by 80.2% and 58.1% compared to 35% and 31% with free HK in the case of MCF-7 and EAC, respectively. HK-loaded NCs inhibited SEC tumor growth by 2.3 fold significantly higher than free HK, in vivo. Conclusion: The designed drug delivery system encapsulating HK exhibited a pronounced decrease in tumor growth biomarkers meanwhile proved its safety in animals. Therefore, 15% PEGylated HK-loaded NCs may act as a promising new approach for breast cancer treatment.

show abstract

Sunflower Seed Oil-Enriched Product Can Inhibit Ehrlich Solid Tumor Growth in Mice

Cited by 18 publications

References 15 publications

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice

<p>Design, Formulation and in vivo Evaluation of Novel Honokiol-Loaded PEGylated PLGA Nanocapsules for Treatment of Breast Cancer</p>

Contact Info

Product

Resources

About